Dai ichi Life Insurance Company Ltd Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Dai ichi Life Insurance Company Ltd grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,707 shares of the medical research company’s stock after buying an additional 168 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Thermo Fisher Scientific were worth $10,953,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Waverly Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 7.1% in the 1st quarter. Waverly Advisors LLC now owns 2,386 shares of the medical research company’s stock worth $1,387,000 after acquiring an additional 158 shares in the last quarter. Tidal Investments LLC boosted its holdings in Thermo Fisher Scientific by 13.4% in the 1st quarter. Tidal Investments LLC now owns 16,728 shares of the medical research company’s stock worth $9,718,000 after buying an additional 1,972 shares during the period. Beacon Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 39.4% in the first quarter. Beacon Capital Management LLC now owns 198 shares of the medical research company’s stock worth $115,000 after buying an additional 56 shares in the last quarter. Brown Shipley& Co Ltd increased its position in Thermo Fisher Scientific by 11.8% in the first quarter. Brown Shipley& Co Ltd now owns 16,025 shares of the medical research company’s stock worth $9,254,000 after purchasing an additional 1,685 shares during the last quarter. Finally, WealthPlan Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 16.6% in the 1st quarter. WealthPlan Investment Management LLC now owns 2,629 shares of the medical research company’s stock valued at $1,528,000 after purchasing an additional 374 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TMO shares. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Sanford C. Bernstein lowered their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Stephens began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Stock Up 0.2 %

Shares of NYSE:TMO opened at $514.05 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $480.57 and a 52-week high of $627.88. The business has a fifty day moving average of $573.70 and a two-hundred day moving average of $579.75. The stock has a market cap of $196.62 billion, a P/E ratio of 32.23, a PEG ratio of 3.39 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.69 earnings per share. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.30%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.